Jun 20 |
Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes
|
May 28 |
Revance to Participate in Upcoming Investor Conferences
|
May 24 |
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
May 23 |
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
|
May 10 |
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript
|
May 10 |
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
|
May 10 |
Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript
|
May 9 |
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
|
May 9 |
Revance Therapeutics GAAP EPS of -$0.58, revenue of $51.94M
|
May 9 |
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
|